eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) Short Interest Update

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 10,700 shares, an increase of 148.8% from the March 31st total of 4,300 shares. Based on an average trading volume of 30,800 shares, the days-to-cover ratio is currently 0.3 days.

eFFECTOR Therapeutics Trading Down 22.1 %

EFTRW traded down $0.01 during mid-day trading on Friday, hitting $0.03. The stock had a trading volume of 28,014 shares, compared to its average volume of 30,854. eFFECTOR Therapeutics has a 1-year low of $0.02 and a 1-year high of $0.21. The stock’s fifty day simple moving average is $0.11 and its 200-day simple moving average is $0.12.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.